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Abstract
Drug-induced liver injury (DILI) cannot be accurately predicted by animal models. In addition, currently available in vitro 
methods do not allow for the estimation of hepatotoxic doses or the determination of an acceptable daily intake (ADI). To 
overcome this limitation, an in vitro/in silico method was established that predicts the risk of human DILI in relation to oral 
doses and blood concentrations. This method can be used to estimate DILI risk if the maximal blood concentration (Cmax) 
of the test compound is known. Moreover, an ADI can be estimated even for compounds without information on blood con-
centrations. To systematically optimize the in vitro system, two novel test performance metrics were introduced, the toxicity 
separation index (TSI) which quantifies how well a test differentiates between hepatotoxic and non-hepatotoxic compounds, 
and the toxicity estimation index (TEI) which measures how well hepatotoxic blood concentrations in vivo can be estimated. 
In vitro test performance was optimized for a training set of 28 compounds, based on TSI and TEI, demonstrating that (1) 
concentrations where cytotoxicity first becomes evident in vitro  (EC10) yielded better metrics than higher toxicity thresholds 
 (EC50); (2) compound incubation for 48 h was better than 24 h, with no further improvement of TSI after 7 days incuba-
tion; (3) metrics were moderately improved by adding gene expression to the test battery; (4) evaluation of pharmacokinetic 
parameters demonstrated that total blood compound concentrations and the 95%-population-based percentile of Cmax were 
best suited to estimate human toxicity. With a support vector machine-based classifier, using  EC10 and Cmax as variables, 
the cross-validated sensitivity, specificity and accuracy for hepatotoxicity prediction were 100, 88 and 93%, respectively. 
Concentrations in the culture medium allowed extrapolation to blood concentrations in vivo that are associated with a 
specific probability of hepatotoxicity and the corresponding oral doses were obtained by reverse modeling. Application 
of this in vitro/in silico method to the rat hepatotoxicant pulegone resulted in an ADI that was similar to values previously 
established based on animal experiments. In conclusion, the proposed method links oral doses and blood concentrations of 
test compounds to the probability of hepatotoxicity.
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Introduction
Accurate prediction of human drug-induced liver injury 
(DILI) based on animal experiments is difficult and is, there-
fore, the leading cause of drug withdrawal from the market 
(Godoy et al. 2013). In vitro methods with primary human 
hepatocytes (PHH) represent a well-established tool to iden-
tify concentrations of test compounds that induce toxicity 
or that cause gene expression alterations (Gebhardt et al. 
2003; Vinken and Hengstler 2018; Braeuning et al. 2018). 
In addition, human hepatocytes engineered to allow in vitro 
expansion and cell lines are frequently used in this context 
(Tolosa et al. 2019; Wink et al. 2018; O’Brien et al. 2006). 
However, the predictive performance of four so far published 
in vitro studies with PHH in 2D and 3D spheroid culture is 
limited, resulting in sensitivities of 51, 66, 59 and 69% and 
accuracies of 71, 71, 67 and 82%, respectively (Xu et al. 
2008; Khetani et al. 2013; Proctor et al. 2017; Vorrink et al. 
2018). Several reasons may be responsible for the limited 
predictive performance in vitro. One is that some studies 
only used PHH from one donor per compound (Proctor et al. 
2017; Vorrink et al. 2018), thus not taking interindividual 
variability into account. A second limitation is that data was 
analyzed using only the margin of safety (MoS) concept (e.g. 
O’Brien et al. 2006), where in vitro testing is performed 
at the maximum concentration of the compound in blood 
(Cmax) multiplied by a factor that usually ranges between 20 
and 100. A positive or negative in vitro test result at this con-
centration leads to a prediction of hepatotoxicity in vivo that 
is then compared to the real in vivo situation. However, test-
ing at concentrations that are more than one order of mag-
nitude above in vivo relevant concentrations is potentially 
problematic, since the mechanisms of toxicity may differ 
between concentrations at Cmax and Cmax × 20. Moreover, it 
is difficult to correctly predict if a drug is safe at therapeutic 
doses when its therapeutic window is relatively narrow. If 
the ratio between toxic and therapeutic blood concentrations 
is 20 or less, for example for acetaminophen (APAP), testing 
at Cmax × 20 (or even Cmax × 100) will result in false positive 
in vitro test results, even if the compound would test nega-
tive at Cmax.
While previous in vitro studies focused on the question 
of whether a compound can be correctly classified as hepa-
totoxic or non-hepatotoxic, the present study additionally 
addresses the possibility of estimating blood concentrations 
and corresponding oral doses that are associated with a spe-
cific risk of hepatotoxicity. We propose the following three 
steps for human hepatotoxicity prediction: (1) determina-
tion of the lowest compound concentrations positive in an 
in vitro test relevant for in vivo hepatotoxicity, (2) extrapola-
tion to in vivo blood concentration, and (3) reverse modeling 
to obtain the lowest oral hepatotoxic dose (Fig. 1a).
Cytotoxicity is usually considered a fundamental read-
out for hepatotoxicity, when investigating the lowest posi-
tive concentration in in vitro testing (Step 1) (O’Brien et al. 
2006; Godoy et al. 2013). However, alterations in gene 
expression or functional changes may already occur at con-
centrations lower than those causing cytotoxicity (Heise 
et al. 2012; Waldmann et al. 2014). For this reason, it may 
be advantageous that in vitro test batteries also include a 
well-chosen set of genes and/or functional readouts in addi-
tion to cytotoxicity (Leist et al. 2017). Step 2, which requires 
extrapolation to the lowest blood concentration that causes 
an increased risk of hepatotoxicity in vivo, assumes that the 
lowest positive concentration in vitro is indicative of the 
lowest blood concentration that causes an increased risk 
of hepatotoxicity (Louisse et al. 2017; Chen et al. 2018; 
Yoon et al. 2015). However, the relationship between the 
lowest positive in vitro and in vivo concentrations has not 
yet been systematically studied. Arguments in favor of this 
assumption are that cultivated PHH may import and export 
chemicals from the culture medium in a manner similar to 
hepatocytes in vivo, which import and export the same com-
pounds from the blood. This also assumes that interactions 
of test compounds with cellular mechanisms occur similarly 
in vitro and in vivo once the test compound has entered the 
hepatocyte. However, it is highly likely that there are differ-
ences between hepatocytes within the intact liver and cul-
tivated PHH (Godoy et al. 2009). Therefore, the exact rela-
tionship between the lowest positive concentrations in vitro 
and in vivo remains to be elucidated. Several mechanisms 
may complicate the establishment of this relationship, with 
pharmacokinetics playing a major role. In vitro concentra-
tions of the compound in the culture medium may initially 
decrease quite rapidly due to adsorption, for example to the 
culture dish, usually followed by a relatively slower decrease 
due to its metabolism by hepatocytes (Kramer et al. 2015). 
In contrast, concentration changes in vivo are usually faster, 
with an initial increase due to absorption from the intes-
tine, followed by a decrease due metabolism and renal as 
well as biliary excretion (Reif et al. 2017; Thiel et al. 2015). 
Moreover, blood has a higher protein concentration than cul-
ture media, which leads to differences between the free and 
protein-bound fraction of test compounds. Finally, cultivated 
PHH do not respond identically to hepatocytes in an intact 
liver, because the isolation and cultivation processes used to 
obtain PHH have been shown to induce changes in hepato-
cellular functions (Godoy et al. 2015, 2016). Extrapolation 
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between blood concentrations and oral doses (step 3) can be 
performed by pharmacokinetic reverse modeling. However, 
it should be considered that this is still associated with a 
degree of uncertainty, although there has been much pro-
gress in physiologically based pharmacokinetic (PBPK) 
modeling in recent years (Jones et al. 2015; Wagner et al. 
2015).
After determining the best strategy to predict hepato-
toxicity, it is important to consider the type of data needed 
(Fig. 1b, c). Repeated oral dosing of mammalian species 
with test compounds leads to blood concentrations that can 
be readily described using pharmacokinetic parameters, such 
as Cmax, half-life, and steady state concentrations (Fig. 1b). 
Reliable information on pharmacokinetics in blood is avail-
able in humans for pharmaceutical drugs and some industrial 
chemicals. For in vitro to in vivo extrapolation it would be 
helpful to know the in vivo test compound concentration in 
the target cells (Fig. 1b). Such information is usually not 
available for hepatocytes and determining intracellular drug 
concentrations in vivo is challenging. However, for marketed 
drugs it is known if certain doses lead to hepatotoxicity or 
are non-hepatotoxic; literature and databases (e.g. https ://
liver tox.nih.gov/) provide information on whether patients 
treated with specific drugs will suffer from mild or severe 
forms of hepatotoxicity. Using in vitro tests with PHH, the 
nominal, i.e., initially established, concentration in the cul-
ture medium applied to the cells, is known (Fig. 1b). Theo-
retically, it would be ideal to directly compare toxicity to 
hepatocytes in vitro and in vivo for known intracellular 
concentrations (dashed line in Fig. 1b). However, the lack 
of knowledge about intracellular concentrations in human 
livers in vivo, and the experimental effort for determining 
intracellular concentrations in vitro, makes this approach 
unfeasible. In contrast, it is possible to study the relation-
ship between the lowest concentrations in vitro that cause 
positive test results (i.e., alteration of a measured param-
eter to a certain extent) and concentrations in blood that 
cause hepatotoxicity in vivo. If this relationship could be 
Lowest concentraon in 
vitro that causes posive 
test results
C
A Step 1 Step 2 Step 3
Reverse 
modelling
Lowest plasma 
concentraon that 
causes an increased risk 
of hepatotoxicity
Lowest oral (repeated) 
dose that causes an 
increased risk of 
hepatotoxicity
In vitro In vivo In vivo
In vitro test 
system with 
hepatocytes
B
Concentraon 
in plasma     
(e.g. cmax)
In vivo
In vitro
Hepatotoxicity
or
no hepatotoxicity
Concentraon in 
target cells, 
hepatocytes
Repeated 
oral doses
Nominal 
concentraon 
in the culture 
medium
Lowest concen-
traon in vitro that 
causes a posive 
test result
Concentraon     
in culvated  
hepatocytes
In vivo - in vitro relaonship
Known
Not 
known
Known
Known
Not known for most 
compounds of the 
present study
Determined in the 
present study
Plasma concentraon in vivo
unknown toxic
Plasma concentraon in vivo
non-toxic unknown
Plasma concentraon in vivo
non-toxic toxic
Known exposure scenario         
(e.g. therapeuc dosing scheme)
Acetaminophen
Up to 4 g per day 10 g per day or more
(1) Hepato-
toxic 
compound
(2) Non-
hepato-
toxic 
compound
(3) Two-
sided
knowledge
(excepon)
Fig. 1  Strategy of the present study. a Concept of in vitro to in vivo 
extrapolation. b In vitro–in vivo relationship. The present study aims 
to predict the lowest compound concentrations in blood that induce 
hepatotoxicity based on the lowest concentrations in vitro that cause 
positive test results. c One-sided knowledge of human hepatotoxicity
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mathematically described, it would represent an important 
step for extrapolating in vitro data to the in vivo situation.
One of the challenges of this proposed strategy is that 
the lowest blood concentration of a test compound that 
causes an increased risk of hepatotoxicity in humans is often 
unknown. Pharmaceutical drugs are administered according 
to specific dosing regimens, and for these therapeutic doses, 
toxicity information is usually available from larger popula-
tion cohorts. Therefore, three scenarios should be considered 
to address this challenge (Fig. 1c). In the first scenario, a 
specific dosing schedule that leads to known blood concen-
trations (e.g. Cmax) causes an increased risk of hepatotoxic-
ity, and as a result higher doses and blood concentrations 
will also be hepatotoxic (Fig. 1c, upper panel). However, 
for most hepatotoxic drugs it is not known by how much 
a dose has to be reduced to decrease the risk of hepato-
toxicity to zero, because patients only receive therapeutic 
doses. In other words, the lowest observed adverse effect 
level (LOAEL) that is routinely determined in animal experi-
ments is not known for most hepatotoxic drugs in humans. 
In scenario two in which a specific dosing schedule and the 
resulting blood concentrations do not cause an increased 
risk of hepatotoxicity, it is usually unknown if higher doses 
would be hepatotoxic (Fig. 1c, middle panel). Therefore, 
it remains open whether 100-fold higher doses would be 
required to reach the hepatotoxic level or if a twofold dose 
escalation is sufficient. Scenario three represents the few 
exceptions for which the human LOAELs are precisely 
known, one example being acetaminophen (Fig. 1c, lower 
panel). Studies have shown that doses of up to 4 g per day do 
not cause an increased risk of hepatotoxicity (Mazaleuskaya 
et al. 2015; Civan et al. 2014), while higher doses of 7–10 g 
from accidental or suicidal intoxications do increase the 
risk of hepatotoxicity. However, for most drugs, the specific 
therapeutic window, hence the toxic threshold in humans 
remains, elusive.
The goal of this study was to establish an in vitro/in silico 
method to estimate the risk of human hepatotoxicity associ-
ated with oral doses and blood concentrations of compounds 
for which this information is unknown. The steps required 
to reach this goal (Fig. 2) include the establishment of new 
performance metrics to optimize the in vitro test with cul-
tivated hepatocytes concerning the input parameters cyto-
toxicity as well as gene expression, and to identify pharma-
cokinetic parameters that can be estimated best by the test 
method. Based on a logistic regression model the risk of 
hepatotoxicity associated with specific blood concentrations 
was calculated. Finally, reverse pharmacokinetic modeling 
was applied to simulate which oral doses lead to these blood 
concentrations. All experiments performed for primary 
human hepatocytes were replicated with HepG2 cells to 
study whether investment into the more expensive primary 
hepatocytes is justified. Although validation with higher 
numbers of compounds is still required, the data presented 
here shows that it is feasible to estimate the acceptable daily 
intake with regard to human hepatotoxicity of an unknown 
compound based on the lowest concentration that causes a 
positive result in the in vitro test.
Materials and methods
Test compounds and concentrations
Detailed information about the test compounds, solvents, 
preparation of stock solutions and covered concentration 
ranges are given in Supplement 1. Background informa-
tion on the individual test compounds, such as the sug-
gested mechanisms of hepatotoxicity, type of liver injury, 
degree of DILI concern, and idiosyncratic mechanisms is 
also available in this supplement. The information whether 
individual drugs cause an increased risk of hepatotoxicity 
was obtained from the database https ://liver tox.nih.gov/ 
and from several other sources listed in Supplement 1 under 
“hepatotoxicity information” and is briefly summarized in 
Table 1. The rationale for the chosen concentration ranges 
Reverse modeling of oral doses associated with a 
specific risk of human hepatotoxicity; in vitro 
definition of the acceptable daily intake (ADI); 
(Fig. 8C,D)  
Extrapolation from in vitro alert concentrations to in vivo 
blood concentrations associated with a specific probability 
to belong to the hepatotoxic or non-hepatotoxic category: 
definition of 0.5; 0.05 and 0.01-probability lines based on 
the SVM classifier (Fig. 8A,B)
Integration of gene expression into the in vitro test system
(Fig. 6; Fig. 7A,B)
Choice of pharmacokinetic parameter to represent in vivo
blood concentration (Fig. 7C)
Establishment of new performance metrics: TSI and TEI
(Fig. 3)
Establishment of a support vector machine (SVM) 
classifier based on the training compounds; plausibility 
check with 8 independent compounds (Fig. 7D)
In vitro test system optimization for cytotoxicity based on TSI 
and TEI for a training set of 16 non-hepatotoxic and 14 
hepatotoxic compounds (Fig. 4,5)
Fig. 2  Working pipeline. The goal of the present study is to esti-
mate oral doses associated with a specific risk of human hepatotox-
icity based on in  vitro data and modeling. The workflow illustrates 
the individual milestones leading to this goal, and the figures with the 
corresponding key results
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was (1) to test high enough concentrations to induce cyto-
toxicity. First choice was to dissolve the test compounds in 
culture medium. If solubility in the culture medium was not 
sufficient to reach cytotoxic concentrations, DMSO was used 
as a solvent, whereby 0.1% DMSO served as a standard con-
centration. Only if 0.1% DMSO was not sufficient to induce 
cytotoxicity, higher concentrations up to 0.5% were applied. 
In all cases controls with identical DMSO concentrations 
were used; (2) to include the in vivo Cmax into the tested 
concentration range.
Primary human hepatocytes
Cryopreserved primary human hepatocytes (PHH) were pur-
chased from BioIVT. Freshly isolated PHH were obtained 
from Hepacult, and the University of Leipzig. The isolation 
of freshly isolated PHH is described in Godoy et al. 2013. In 
total, PHH from 17 different donors were used. The donor 
characteristics are given in Supplement 2. Cytotoxicity 
experiments were performed exclusively with cryopreserved 
PHH. Gene expression experiments were performed with 
both freshly isolated and cryopreserved PHH.
Cell culture of PHH and HepG2 cells
In the current study, cryopreserved PHH, freshly isolated 
PHH, and the HepG2 cell line (ATCC number: HB-8065™) 
were used. The identity of the HepG2 cells was confirmed by 
short tandem repeat (STR) profiling once a year by DSZM 
(Leibniz Institute DSMZ-German Collection of Microor-
ganisms and Cell Cultures). Cryopreserved PHH were cul-
tured according to a published standard operating procedure 
(SOP) (Gu et al. 2018 supplement 2). Culture of freshly iso-
lated PHH followed a published standard protocol (Grinberg 
et al. 2014). The SOP for the cultivation of HepG2 cells is 
given in Supplement 3A.
Cytotoxicity analysis with PHH and HepG2 cells
The cytotoxicity assay with PHH was performed using the 
CellTitre-Blue (CTB) assay as described in Gu et al. (2018) 
according to the SOP in Supplement 3A. The same cyto-
toxicity assay was also used for HepG2 cells (Supplement 
3A). William’s E medium for cultivation of PHH contained 
11 mM glucose, while Dulbecco’s Modified Eagle’s Medium 
(DMEM) used for HepG2 cells contained 25 mM glucose. 
The glucose concentrations indicated in the results section 
were reached by adding glucose accordingly. All tested con-
centrations of the compounds and solvents are given in Sup-
plements 1, 4 and 5.
Gene expression analysis in PHH and HepG2
Expression analysis of seven genes (CYP1B1, CYP3A7, 
SULT1C2, FBXO32, TUBB2B, G6PD and RGCC ) was per-
formed by real-time quantitative reverse transcription PCR 
(qRT-PCR). TaqMan probes for the seven genes, as well as 
two housekeeping genes (GAPDH and UBC), were obtained 
from Applied Biosystems. The SOPs for the treatment of 
cells, isolation of RNA, reverse transcription, primers, and 
qRT-PCR conditions are given in Supplement 3A. For the 
analysis of gene expression freshly isolated and cryopre-
served hepatocytes were used (Supplement 2). Donor char-
acteristics and the donor used for analysis of each compound 
and experiment are given in Supplement 2. Gene expression 
was calculated relative to the expression of the housekeeping 
genes GAPDH and UBC as described in Supplement 3A. 
Only samples with a stable expression of the housekeeping 
gene  (deltahousekeeper ≤ 0.5) were further analysed.
Glutathione depletion assay in HepG2 
for evaluating the oxidation stress
HepG2 cells (15,600 viable cells in 200 µl DMEM) were 
seeded in black, clear-bottomed 96-well plates (Sigma 
Aldrich), 24  h prior to exposure to test compounds as 
described in Supplements 1, 4 and 5. After 48 h of expo-
sure, the cell culture medium was removed and the cells 
were incubated with 0.5 µg/ml Hoechst 33342 diluted in 
culture medium for 30 min at 37 °C, to stain the nuclei of 
the living cells. After the incubation period, fluorescence 
was measured at an excitation wavelength of 340 nm and 
emission wavelength of 450 nm using a spectrophotometer 
(TECAN SpectraFluor Plus). The media containing Hoe-
chst 33342 were removed, the cells were washed once with 
warm PBS and then incubated with 100 µl of 40 µM dibro-
mobimane (Sigma Aldrich) diluted in PBS for 30 min at 
37 °C. To determine background fluorescence, wells without 
cells that were incubated with dibromobimane (40 µM) in 
PBS were included. Fluorescence was measured at an exci-
tation wavelength of 393 nm and an emission wavelength 
of 477 nm. To determine the glutathione (GSH) levels, the 
background fluorescence for dibromobimane was subtracted 
from the values obtained in wells that contained cells, and 
these background-corrected fluorescence values were nor-
malized to the live cell number reflected by the fluorescence 
signal of Hoechst 33342. The normalized values were then 
used to fit a dose–response curve, as described below. The 
concentrations used are given in Supplement 5. An SOP of 
the glutathione assay is given in Supplement 3A.
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Statistical analysis
All statistical analyses were performed with the statistical 
programming language R-version 3.5.1 (https ://www.R-
proje ct.org/).
Curve fitting and calculation of EC values
The raw data were processed as follows: CellTitre-Blue 
 Reagent® was used to evaluate the cell viability. Background 
controls (fluorescence values from CellTiter-Blue  Reagent® 
mixed with medium that was not in contact with cells) were 
subtracted from each data point. Replicates of control val-
ues were averaged for each biological replicate separately. 
Next, fluorescence values of all samples were divided by 
the corresponding averaged control values and multiplied by 
100 to obtain percentages. Based on the assumption that the 
concentration–response relationship can be described by a 
sigmoidal curve, a four-parameter log-logistic model (4pLL) 
was fitted to the data using the R package drc version 3.0-1 
(Ritz et al. 2015). For a concentration x and four parameters 
b, c, d, e, the response is given by:
where c and d are the values of the right and left asymp-
tote, respectively, b is the slope and e is the concentration at 
which 50% of the overall effect is observed. For given con-
centrations and background-corrected, normalized response 
values, the parameters were estimated numerically according 
to the least square method with the Gauss–Newton algo-
rithm. The above described curve fitting procedure can lead 
to a left asymptote that reaches values higher or lower than 
100%. To ensure that the left asymptote attains a value of 
100%, a refit-procedure was conducted. All response values 
were divided by the value of the left asymptote after the first 
fit and again multiplied by 100 to obtain percentages. The 
4pLL model was again fitted to the data.  ECk values were 
calculated as the concentration where the sigmoidal curve 
attains the value (100 − k)% (e.g.  EC10 corresponds to the 
concentration where the sigmoidal curve reaches the value 
90%). To assess the quality of the curve-fit, a goodness-of-
fit statistic was calculated as 1 − [(the sum of squared dif-
ferences between the data points and the fitted curve)/(the 
sum of squared differences between the data points and the 
mean response)], which gives values near 1 for a good fit and 
values near 0 for a poor fit; curves with goodness-of-fit of at 
least 0.55 were used to derive  ECk values for further analy-
sis. Confidence intervals of the EC values were calculated 
by the delta method which approximates the variance of the 
inverse function of f (Grinberg 2017).
f (x|b, c, d, e) = c + d − c
1 + exp (b(log (x) − log (e)))
,
The above described procedure for the determination of 
EC values may result in values lower or higher than the actu-
ally tested concentrations. The calculated EC values were 
only accepted if they were within the interval  [concmin/5, 
 concmax × 5], whereby the choice of a range of five serves to 
avoid EC-values too far from the lowest and highest tested 
concentrations. Values below  concmin/5 were set to “< con-
cmin/5” and values above  concmax × 5 were set to “> conc-
max × 5”. Cases in which the respective EC value could not 
be calculated, because the function never reached the target 
value on the y-axis (e.g., 50% for the  EC50), were set to 
“> concmax”.
In subsequent analyses, the median EC value of the three 
biological replicates was used for each compound. Alter-
natively, the minimum or the maximum of three EC values 
was used. When one or more of the three EC values were 
outside of the acceptable interval (< concmin/5 or > conc-
max × 5), the following rules were applied to ensure that mini-
mum, median and maximum EC values were available: (i) 
if a donor had an EC value < concmin/5, it was replaced by 
 concmin/5; (ii) if a donor had an EC value > concmax × 5, it 
was replaced by  concmax × 5. The effective concentrations 
are given in Supplement 6, the fitted curves are shown in 
Supplement 7A-C and the goodness of fit is summarized in 
Supplement 8.
Calculation of toxicity separation and estimation indices
Two indices were established, the toxicity separation index 
(TSI), which quantifies how well a test method differentiates 
between hepatotoxic and non-hepatotoxic compounds, and 
the toxicity estimation index (TEI), which measures how 
well hepatotoxic blood concentrations in vivo can be esti-
mated by an in vitro test system. Input data for the calcula-
tion of both TSI and TEI are in vitro (e.g.  EC10,  EC50) and 
in vivo (e.g. Cmax, AUC) concentrations. A detailed descrip-
tion how the TSI and TEI are calculated, with specific exam-
ples, is given in Supplement 3B.
Briefly, to calculate the TSI, the difference between the 
in vivo concentration for a given exposure scenario and the 
positively tested in vitro concentration is calculated on log10 
scale for each compound. The differences are then sorted in 
ascending order and for each interval between two consecu-
tive differences, a cutoff value, is chosen. For each cutoff 
value a prediction of the toxicity status (hepatotoxic or non-
hepatotoxic) of each compound is performed and compared 
to the true toxicity status. Thereby, sensitivity and specificity 
can be calculated for each cutoff. 1-specificity is then plot-
ted against sensitivity for each cutoff value and the TSI is 
calculated as the AUC, i.e., the area under the ROC curve. 
The R package pROC version 1.13 was used (Robin et al. 
2011). A TSI of 1 is optimal since it coincides with the 
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perfect separation of toxic and non-toxic compounds, while 
a TSI of 0.5 is obtained for a random class assignment to 
the compounds.
To calculate the TEI, non-toxic compounds are excluded. 
The TEI is calculated as:
where i = 1,…, n represent the compounds in question, x(i) 
and y(i) the in vitro value and the in vivo value of compound 
i, respectively, and 1(condition)(i) the indicator function which 
takes the value 1 if the condition is fulfilled by the com-
pound i, otherwise 0. A value of 1 represents the optimal 
value of the TEI. In case of missing in vitro alerts a penalty 
factor was used (Supplement 3B).
Hepatotoxicity prediction
A support vector machine (SVM) was used to classify com-
pounds as hepatotoxic or non-hepatotoxic, employing cyto-
toxicity median  EC10 values (48 h compound incubation) and 
Cmax (total concentration; 95% percentile) as input variables. 
The classification performance was assessed using leave-one-
out cross validation with 30 iterations. With this approach, 
one compound is left out and a classifier is constructed using 
variables from the remaining compounds and their toxicity 
status (i.e., hepatotoxic or non-hepatotoxic) as input. Next, the 
classifier is used to predict whether the left-out compound was 
hepatotoxic or not. This procedure is then repeated until all 
compounds were left out once. The original data points can be 
considered to lie in a vector space where the number of dimen-
sions corresponds to the number of input variables. The aim is 
to identify a hyperplane, which separates the observations of 
the two classes (hepatotoxic and non-hepatotoxic). Since only 
two input variables (in vivo Cmax and in vitro median  EC10) 
were used in the analysis finally presented in Fig. 7d, the vector 
space was a two-dimensional coordinate system and the hyper-
plane a straight line. The line was chosen to maximize the size 
of the margin (i.e., the minimal distance from all data points 
to the line) and simultaneously constrain the sum of errors by 
a given constant C (i.e., misclassifications are allowed when 
the data cannot be perfectly separated by a straight line). The 
R package mlr version 2.13 (Bischl et al. 2016) was used as a 
framework for classifier training and evaluation, and the pack-
age kernlab version 0.9-27 (Karatzoglou et al. 2004) for the 
SVM classification. Default settings were used for the hyper-
parameter. In addition to the allocation of the compounds to 
one of the two groups, the probability of group membership 
was calculated using a logistic regression model fitted to the 
differences between the data points and the separating line 
TEI = 1 −
1
5
∑n
i=1
1toxic(i)1x(i)>y(i)
����log10
�
y(i)
x(i)
�����∑n
i=1
1toxic(i)
.
(Platt 2000). The separating line between the two categories 
(hepatotoxic and non-hepatotoxic) corresponds to a probability 
of 50% to belong to the hepatotoxic compounds. Based on the 
fitted logistic regression model a distance from the separat-
ing line can be determined for any other probability. By this 
method lines parallel to the separating line with probabilities 
of 10, 5, 1, 0.5 and 0.1% were defined.
Simulation of pharmacokinetics
For each of the test compounds, a physiologically based 
pharmacokinetic (PBPK) model was constructed using the 
Simcyp Simulator (commercial software, Version 15; Sim-
Cyp, Sheffield, UK). The input parameters used to describe 
the compounds within the human PBPK models are given in 
Supplement 3C and Supplement 9). The performance of the 
PBPK model for each compound was assessed by comparing 
the simulated concentrations of the compounds in blood with 
available data. The simulations were performed in populations 
of virtual individuals who reflected a European population in 
terms of age and sex. In this exercise, if the drug or chemical 
was known to have a significant circulating metabolite (e.g., 
aspirin with its metabolite salicylic acid), both the parent and 
metabolite were simulated. If a compound was known to be 
significantly metabolised by an enzyme that is polymorphi-
cally expressed in the population, e.g., CYP2D6, simulations 
were conducted for both the extensive and poor metaboliser 
phenotypes. A potential limitation of the adopted approach 
in the fit for purpose models described here is that the role of 
hepatic uptake in the disposition of the compounds was not 
considered. Once the initial PBPK model was constructed and 
the performance checked against clinical data, models were 
refined as required to produce a model that better described 
the clinical data. Finally, simulations were conducted for 
each of the compounds at the specified doses in a popula-
tion of 100 North European Caucasian subjects (age 20–50, 
50% female). Multiple dose simulations were conducted for a 
long enough period to ensure that steady state concentrations 
were achieved. From the simulations, the Cmax, Cmax portal 
vein and average steady-state concentration cav, ss (AUC 0−t/
dosing interval) were calculated for both the first dose and at 
steady-state. The mean values in the population as well as the 
concentrations corresponding to the 5th and 95th percentiles 
of the population were calculated.
Results
Establishment of metrics for evaluation of in vitro 
test method performance
To evaluate the performance of an in vitro test method, 
two new metrics—the toxicity separation index (TSI) and 
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toxicity estimation index (TEI)—were introduced, where 
TSI considers the separation of hepatotoxic from non-hepa-
totoxic compounds, and TEI estimates how well hepatotoxic 
blood concentrations in vivo can be estimated for hepato-
toxic compounds (Fig. 3). Assessment of in vitro test meth-
ods using these two indices may be advantageous, because 
the general performance of different methodological alter-
natives can be compared, for example different cytotoxicity 
cutoffs or the inclusion of additional readouts for a given 
set of compounds. Once an optimized test method has been 
established, it can then be applied to independent com-
pounds where the performance is assessed in standard terms, 
such as sensitivity and specificity.
Both TSI and TEI are calculated based on the projec-
tion of a predefined battery of test compounds onto a two-
dimensional coordinate system, where the x-axis indicates 
TSI: How well a test system differenates between hepatotoxic and non-hepatotoxic compounds
TEI: How well hepatotoxic blood concentraons in vivo can be esmated by an in vitro test system for
hepatotoxic compounds
TEI: Toxicity Esmaon IndexTSI: Toxicity Separaon Index Hepatotoxic Non-hepatotoxic
A B
C D
Fig. 3  a–d Concept of the toxicity separation (TSI) and toxicity estimation (TEI) indices (color figure online)
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the lowest concentrations that cause a positive test result (‘in 
vitro alert’, such as decreased viability or increased expres-
sion of genes) of any test method, and the y-axis indicates 
the in vivo blood concentrations (e.g., Cmax) that result from 
a specific dosing schedule. In this in vitro-to-in vivo extrapo-
lation plot (shortened: ‘extrapolation plot’), each test com-
pound is represented by a symbol. Red and green color indi-
cate whether the individual compounds cause an increased 
risk of hepatotoxicity (red) or are non-hepatotoxic (green) 
at the corresponding Cmax. For ease of understanding, the 
principles of TSI and TEI are illustrated with hypothetical 
scenarios (Fig. 3a–d). TSI measures how well a test method 
differentiates between hepatotoxic and non-hepatotoxic com-
pounds. It covers a range from 0.5 to 1.0, where a TSI of 1.0 
indicates a perfect separation, while 0.5 represents a ran-
dom result. The hypothetical examples illustrate both good 
(Fig. 3a, b) and poor (Fig. 3c, d) separation of hepatotoxic 
and non-hepatotoxic compounds. The concept of separation 
in such a plot is based on the assumption that the differ-
ence between the in vitro alert concentration and its corre-
sponding concentration in vivo is larger for non-hepatotoxic 
than for hepatotoxic compounds. The diagonal line in the 
extrapolation plot indicates a hypothetical situation where 
the in vitro alert concentration exactly corresponds to the 
in vivo hepatotoxic blood concentration for the hepatotoxic 
compounds (‘iso-concentration line’).
TEI measures how accurately an in vitro test method 
estimates hepatotoxic blood concentrations in vivo; in other 
words—it measures how far the red points are below the 
iso-concentration line, e.g., a TEI of 1 indicates a position 
where all hepatotoxic compounds (red points) are on the iso-
concentration line or above. Therefore, shifting all points in 
Fig. 3a downwards leaves the TSI unchanged, but decreases 
the TEI, as shown in Fig. 3b. If all points lie on, or very 
close to, the iso-concentration line, as in Fig. 3c, the TEI 
is high, but the test method has no, or only little, discrimi-
natory power (i.e., low TSI). Finally, shifting the points in 
Fig. 3c downwards results in both poor TSI and poor TEI 
(Fig. 3d). When designing a good in vitro method, priority 
is given to obtaining a high TSI, since the first objective is 
to discriminate whether a compound is hepatotoxic or not. 
A high TEI is also desirable but should not be achieved at 
the expense of a worse TSI, since this metric is only relevant 
once hepatotoxic compounds have been reliably identified.
Once an extrapolation plot has been established for a set 
of hepatotoxic and non-hepatotoxic compounds, it can then 
be used to assess additional substances without having infor-
mation on their hepatotoxicity by adding them to the existing 
plot. The position on the x-axis is determined in vitro, while 
additional knowledge is required for the y-axis location.
In vitro data generation and PBPK modeling
This chapter gives an overview over the generated data, 
while the actual application as summarized in the working 
pipeline (Fig. 2) follows in the next chapters. For in vitro 
test system optimization with concrete TSI and TEI values, 
the lowest concentrations of 28 test compounds that caused 
a positive result in vitro were presented on the x-axis of 
the extrapolation plot, and the blood concentrations (Cmax) 
established by PBPK modeling were plotted on the y-axis. 
To generate the required data, PHH from three donors were 
used to perform concentration-dependent cytotoxicity analy-
ses of the 28 compounds using the (CTB) assay according to 
a published standard operation procedure (Fig. 4a, left panel; 
Supplement 3A). After fitting a sigmoidal dose–response 
curve, EC values ranging from  EC10 to  EC80 with a step-
wise increase of 10 were calculated. Figure 4b illustrates 
the example of the  EC10 for one compound (clonidine, 
CLON) in PHH. The raw data generated from the 28 com-
pounds tested in PHH from three donors at five concentra-
tions plus solvent controls are available in Supplement 4. 
An overview of the  EC10 values for all compounds is given 
in Table 1. In a subsequent step, expression of a previously 
published seven-gene panel (CYP1B1, CYP3A7, TUBB2B, 
SULT1C2, G6PD, RGCC and FBXO32) (Grinberg et al. 
2014) was determined in a concentration-dependent man-
ner in cultivated PHH from three donors for the 28 com-
pounds. The results for one compound (valproic acid, VPA) 
are shown in Fig. 4c; data obtained for all compounds and 
donors are available in Supplement 4 and 6. Cytotoxicity 
and the expression of the seven genes was also determined 
Fig. 4  In vitro data generation and PBPK modeling. a Exposure 
schedules for cytotoxicity tests with cultivated primary human hepat-
ocytes (PHH) and HepG2 cells. Schedules of all in  vitro tests used 
in the present study and the corresponding standard operation proce-
dures are in Supplement 3. b Concentration response curve of cyto-
toxicity in PHH for clonidine (CLON) as an example. The vertical 
lines indicate the  EC10 value and its 95% confidence interval. Cyto-
toxicity data of all test compounds, including the raw data are in Sup-
plement 7. c Expression data of the 7-gene signature, for the example 
of valproic acid (VPA) in PHH. The lowest positive test concentration 
is defined as the lowest concentration at which one of the seven genes 
exceeds expression of the corresponding solvent control by a factor 
of 2.5 (red line). The error ranges are standard errors of the mean 
(SEM) of three independent experiments. Expression data of all test 
compounds, including the raw data, are in Supplement 4, 5 and 6. d 
Example of cytotoxicity analysis (clonidine; CLON) in HepG2 cells. 
e Example of expression analysis in HepG2 cells for valproic acid 
(VPA). f Example of glutathione depletion analysis in HepG2 cells. g 
Illustration of pharmacokinetic parameters for the example carbamaz-
epine. Cmax: maximal blood concentration (total concentration, i.e., 
free and protein bound); Cmax steady state: maximal blood concentration 
in the steady state; Cav steady state: average blood concentration in the 
steady state. h Correlation plots of Cmax and Cmax, in steady state, as 
well as Cmax in whole blood (of the general circulation) and Cmax in 
blood of the portal vein. Each symbol represents one test compound. 
The lines crossing the symbols indicate the ranges between 5th and 
95th percentiles. The complete set of PBPK modeling data is given in 
Supplement 10 (color figure online)
◂
1620 Archives of Toxicology (2019) 93:1609–1637
1 3
in a concentration-dependent manner for HepG2 cells in 
three independent experiments, as done for PHH (Fig. 4a, 
right panel, d, e, Table 1, Supplement 5, 6). Moreover, GSH 
depletion was measured as an additional in vitro endpoint 
in HepG2 cells for evaluation in a pilot study (Fig. 4f) as 
described below. The processed data for PHH and HepG2, 
all fitted curves and the goodness of fit for these curves are 
given in Supplements 6, 7 and 8.
Pharmacokinetic modeling was performed for oral dos-
ing schedules used in clinical routine (Supplement 9). For 
all compounds, the blood Cmax, Cmax at the steady state 
(Cmax,ss) and the average concentration at steady state (Cav,ss) 
(Fig. 4g) were calculated for (a) total concentration (pro-
tein bound plus free compound) in blood from the general 
circulation, (b) free, non-protein bound concentrations in 
blood from the general circulation, and (c) total concentra-
tions (protein bound plus free compound) in blood from the 
portal vein (Supplement 9). Besides pharmacokinetic mod-
eling, a comprehensive literature search was performed for 
experimentally analyzed blood concentrations for the dif-
ferent test compounds (Supplement 6). All pharmacokinetic 
parameters correlated with one another (Supplement 10). 
One example of the correlation plots for total (protein-bound 
and unbound) concentrations in the general circulation of 
Cmax versus Cmax,ss is illustrated in Fig. 4h, where Cmax,ss 
was only slightly higher than Cmax for most compounds. In 
a second example, the correlation plot of Cmax in the gen-
eral circulation versus the corresponding concentration in 
the portal vein shows that portal vein concentrations can be 
higher than concentrations in the general circulation, which 
is plausible for orally administered compounds with a high 
first pass effect (Fig. 4h). Correlation plots for pharmacoki-
netic parameters and physicochemical properties with blood 
concentrations of the study compounds are given in Supple-
ment 10. As expected, the daily dose of the test compounds 
strongly correlates with the Cmax in blood (Supplement 
10A); Cmax of the hepatotoxic compounds is higher com-
pared to the non-hepatotoxic substances. Moreover, a weak 
inverse correlation between hydrophobicity and Cmax was 
observed (Supplement 10B), whereas Cmax showed a weak 
inverse correlation with the molecular weight of the tested 
compounds (Supplement 10C). Key parameters, including 
Cmax,  EC10 (median of the three donors), and the lowest 
positively tested concentrations of the seven genes are sum-
marized in Table 1, and the complete set of data is available 
in Supplements 1, 6, and 9.
An important aspect for test development is whether spe-
cific dosing regimens of drugs (or specific levels of exposure 
to environmental compounds) lead to an increased probabil-
ity of hepatotoxicity. This information is given in Table 1 
(sources and details in Supplement 1) for the dosing sched-
ules summarized in Supplement 9. For most of the drugs in 
Table 1, reliable information was only available for one (or 
for a few similar) therapeutic dosing schedule. An excep-
tion is acetaminophen where not only non-hepatotoxic doses 
and therapeutic blood concentrations are available, but also 
comprehensive data from overdoses that lead to hepatotoxic-
ity (Table 1 and, Supplement 9). Therefore, acetaminophen 
appears twice in Table 1, with a hepatotoxic and a non-
hepatotoxic blood concentration. Besides pharmaceutical 
compounds, certain chemicals (ethanol, dimethyl sulfoxide, 
glucose monohydrate, methylparaben and triclosan) were 
also included (Table 1). Ethanol was considered, because 
large studies are available that provide information on doses, 
and associated blood concentrations, leading to liver damage 
when exposure continues over longer periods of time (Sup-
plement 9). In contrast, the very low ethanol blood concen-
trations observed after transdermal exposure during hand 
disinfection can be considered non-hepatotoxic. Therefore, 
ethanol also appears in Table 1 with both a hepatotoxic and 
a non-hepatotoxic Cmax.
In vitro test optimization based on cytotoxicity
The above-introduced concept of TSI and TEI was applied 
to the 28 test compounds to determine which cytotoxicity 
parameter (EC-threshold, incubation period) is optimal 
(x-axis), while Cmax (total concentration; 95% population 
percentile; y-axis) was kept constant. When PHH from three 
donors were tested for cytotoxicity, the first question to be 
answered was from which donor the cytotoxicity data should 
be used, the median, minimum or maximum. A second 
important question was whether the often-used  EC50 value 
is optimal or if other EC values  (EC10up to  EC80) are supe-
rior. To systematically address these questions, extrapolation 
plots were generated, considering all the different param-
eters for the x-axis, and the corresponding TSI and TEI 
were determined and plotted against each other (Fig. 5a). 
Higher TSI values were obtained when the median donor 
values were used, compared to the corresponding minima 
and maxima (Fig. 5a). Moreover, a consistent and relatively 
strong decrease in TEI was obtained when EC values were 
increased from  EC10 to  EC80. This was observed for the min-
imum, maximum, as well as the median values (Fig. 5a). 
Based on these results, the median  EC10 value was chosen 
for further analysis of cytotoxicity.
A third question was how long cultivated PHH should 
be exposed to the test compounds for cytotoxicity testing. 
In the present study, an incubation period of 48 h was used. 
Additionally, incubations of 24 h and 7 days (with repeated 
culture medium changes with fresh test compound) were 
performed as previously reported (Gu et al. 2018). A higher 
TSI was obtained for the 48 h compared to the 24 h and 
7 day incubation periods (Fig. 5b). This observation was 
independent of the EC cutoff, as exemplified for  EC10,  EC20 
and  EC50 in Fig. 5b. Therefore, the median  EC10 with 48 h of 
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Fig. 5  Test system optimization for cytotoxicity. a Relationship 
between EC value  (EC10,  EC20, to  EC80) and TSI as well as TEI. 
EC values are given for the hepatocytes from three donors, red color 
representing the most susceptible (minimum), blue the median, and 
green the most resistant (maximum) donor. The intensity of the dots 
represents the respective EC values with the darkest dots represent-
ing the respective  EC10 values and the lightest dots representing the 
respective  EC80 values. b Relationship between incubation period (1, 
2 and 7 days) and TSI as well as TEI. c Extrapolation plot of the  EC10 
of the median donor. Each compound was tested with hepatocytes 
from three donors. To illustrate interindividual variability, the  EC10 
values for each individual donor are given by a diamond, and the 
three diamonds corresponding to one test compound are connected by 
a line. The vertical lines crossing each median  EC10 value illustrate 
the ranges between 5th and 95th percentiles of Cmax (total maximal 
blood concentrations). The 95th percentile coincides with the median 
diamond, the horizontal dashes below are median values and 5th per-
centiles. Dashed diagonal line: iso-concentration line (identical con-
centrations in  vivo and in  vitro). The key for the abbreviated com-
pound names is given in Supplement 1 (color figure online)
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compound exposure were used to generate an extrapolation 
plot (Fig. 5c). Each compound was identified by an abbrevia-
tion defined in Table 1, where red and green symbols indi-
cate hepatotoxic and non-hepatotoxic compounds, respec-
tively. In general, hepatotoxic compounds were located 
above the non-hepatotoxic compounds. This resulted in an 
almost optimal TSI of 0.996 but a lower TEI of 0.844, since 
most of the hepatotoxic compounds clustered below the iso-
concentration line (Fig. 5c).
Integration of gene expression into the in vitro test
Next, we evaluated if adding gene expression as an addi-
tional readout to the optimized version of the test method 
obtained above could further improve its performance. 
For this purpose, seven genes (Fig. 4c, e) were selected 
from a previously published study analyzing genome-wide 
expression data in cultivated human hepatocytes of 143 
compounds (Grinberg et al. 2014). The selection criteria 
were (1) gene expression increased by many compounds; 
(2) gene expression increased in human liver disease (stea-
tosis, fibrosis and cirrhosis) to support in vivo relevance; 
and (3) gene expression not altered by the hepatocyte iso-
lation and cultivation procedure. Although the goal was to 
include gene expression into the test battery together with 
cytotoxicity, the seven genes were initially analyzed alone 
and in combination (without cytotoxicity). Extrapolation 
plots were generated, which included each of the seven 
genes individually, with the lowest as well as the median 
and the maximum compound concentrations that induced 
gene expression plotted on the x-axis, and the Cmax on the 
y-axis (Fig. 6a–g). To identify an appropriate cutoff, an 
analysis of TSI and TEI was performed where all seven 
genes were considered. Gene expression at a specific test 
compound concentration was defined as positive if the 
expression of the most sensitive gene increased 1.5-fold; 
this cutoff value was increased to 5.0-fold in steps of 0.1 
(Fig. 6i). A maximal TSI was obtained for cutoffs ranging 
between 2.1 and 2.6; therefore, a cutoff of 2.5 was fur-
ther used to define a positive test result. A comparison of 
the median and the minimum alert concentration among 
the three donors (with a 2.5-fold cutoff) demonstrated 
that using the median leads to a higher TSI (Fig. 6j). The 
maximum gene expression alert concentrations (the most 
resistant donor) are not shown, because more compounds 
did not reach the cutoff of 2.5-fold, which would lead to 
the disadvantage of a high number of compounds without 
in vitro alert. Together, these results justify the use of a 
2.5-fold gene expression cutoff for the median donor for 
further analyses.
The data of the individual genes (Fig. 6a–g) showed 
that only some of the compounds generated a positive test 
result in the gene expression assay. Despite this limitation, 
a relatively good separation of hepatotoxic and non-hepa-
totoxic properties was possible for the substances that did 
reach an alert concentration. Therefore, a combined analy-
sis of all seven genes was performed, and a concentration 
defined as positive when at least a 2.5-fold increase was 
obtained for the median alert concentration per compound, 
for at least one gene (Fig. 6h). Even under these condi-
tions, three hepatotoxic  (ETOHhigh, LAB, LEV) and seven 
non-hepatotoxic  (ETOHlow, FAM, GLC, HYZ, MEL, PPL, 
and TSN) compounds did not generate an alert. The results 
show that gene expression may support the differentiation 
of hepatotoxic and non-hepatotoxic compounds, but only 
if an alert concentration is observed; however, with only 
seven genes not all test compounds can be assessed.
A subsequent goal was to study if TSI or TEI can be 
improved by combining cytotoxicity (median  EC10, 48 h 
incubation) with gene expression. For this purpose, all 
possible combinations (n = 128) of gene expression—for 
zero up to seven genes—with cytotoxicity were analyzed 
(Supplement 11). In each combination, the readout (alert 
of median gene expression or  EC10) that resulted in the 
lowest positively tested concentration was considered. 
None of the combinations improved TSI beyond 0.996, 
which was already achieved by the median  EC10 alone. 
However, the TEI of  EC10 (0.844) was improved by addi-
tionally considering gene expression (Fig. 7a). CYP1B1 
and CYP3A7 were of particular relevance in the combined 
scenario. When three genes were considered—CYP1B1 
and CYP3A7 and a third gene (G6PD, SULT1C2, or 
TUBB2B)—a maximal TEI of 0.887 was obtained. Adding 
further genes, up to all seven, did not further improve the 
TEI (Fig. 7a). In conclusion, a combination of cytotoxicity 
(median  EC10, 48 h incubation) and the expression of three 
genes as specified above resulted in optimal TSI and TEI 
for the analyzed set of compounds, as illustrated in Fig. 7b.
Fig. 6  Expression of seven genes in relation to human hepatotoxicity. 
a–g Results for each of the seven genes, CYP3A7, CYP1B1, G6PD, 
SULT1C2, FBXO32, RGCC , and TUBB2B. The x-axis gives the low-
est positive test compound concentrations, based on an at least 2.5-
fold median increase over solvent controls. The y-axis represents the 
Cmax (total maximal blood concentration, 95% CI). Red and green 
symbols represent hepatotoxic and non-hepatotoxic compounds, 
respectively. Compounds that did not increase expression of the cor-
responding genes by at least 2.5-fold are listed under “no alert” in the 
right column of each plot. h Combination of the seven genes. The 
x-axis gives the lowest alert (at least 2.5-fold increase of the median) 
achieved by the most responsive of the seven genes. i Variation of the 
cutoff for definition of positive test results for the lowest alert result-
ing from expression analysis of the seven genes. The cutoff (median) 
was varied between 1.5 and 5.0 in intervals of 0.1. j TSI and TEI for 
each of the seven genes. Circles represent the analysis of the median, 
triangles of the most susceptible donor (minimum). Dashed lines in 
a–h are iso-concentration lines (color figure online)
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Choice of pharmacokinetic parameter to represent 
in vivo blood concentration
To determine the best factor to represent in vivo blood con-
centration, the pharmacokinetic parameter on the y-axis was 
varied, while keeping the cytotoxicity parameter (median 
 EC10, 48 h incubation) constant on the x-axis. Key ques-
tions were to identify which of the following parameters 
are superior (Fig. 7c): total or free concentrations; concen-
trations in blood of the general circulation or in the portal 
Toxic
Non-toxic
True status
Toxic
Non-toxic
Predicted status
Performance measures of 
training compounds:
Sensivity:  100.0%
Specificity:    87.5%
Accuracy:       93.3%
A D
B
C
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vein; the use of pharmacokinetic parameters (e.g. Cmax) of 
the 95% percentile, mean or 5% percentile of a population; 
maximal blood concentrations (Cmax), maximal blood con-
centrations in the steady state (Cmax ss) or average blood con-
centrations in the steady state (Cav, ss). The modeled pharma-
cokinetic parameters are available in Supplement 9. Plotting 
TSI against TEI for all pharmacokinetic parameters, led to 
the following findings for the analyzed set of compounds 
(Fig. 7c): (1) the use of total blood concentrations (orange 
symbols) resulted in higher TSI and TEI than free drug con-
centrations (blue symbols); (2) blood concentrations of the 
test compounds in the general circulation (e.g., the orange 
and red symbols) resulted in higher TSI, but lower TEI than 
concentrations in the portal vein after oral uptake (green 
symbols); (3) PBPK modeling allows simulation of interin-
dividual differences, differentiating for example, the mean 
blood concentrations, as well as concentrations in the high-
est 5% (95th percentile) and the lowest 5% (5th percentile) 
of a human population. The use of the 95th percentiles led 
to higher TSI and TEI than the corresponding 5th percen-
tiles and the mean; and (4) the use of Cmax led to a slightly 
higher TSI than Cmax ss and clearly higher TSI and TEI than 
Cav, ss. In summary, the use of total (free and protein bound) 
Cmax of the 95th percentile leads to the best TSI based on 
in vitro data (cytotoxicity,  EC10, median), while portal vein 
concentrations lead to higher TEI at the expense of a reduced 
TSI (Supplement 11). Therefore, the total Cmax of the 95th 
percentile was used for the next step in the pipeline (Fig. 2), 
the establishment of the classifier for the prediction of hepa-
totoxicity status.
Prediction of hepatotoxicity and non‑hepatotoxicity 
by SVM classification
Once the optimized parameters had been established based 
on TSI and TEI, the test system was used to evaluate whether 
compounds were hepatotoxic or non-hepatotoxic. When 
projected onto the known compounds in the extrapolation 
plot, the location of a compound with unknown hepatotoxic-
ity status allows for a visual assessment (qualitative) of its 
potential toxicity. However, an objective categorization of 
compounds as hepatotoxic or non-hepatotoxic requires the 
use of a classification algorithm. Here, a SVM classifier was 
used to classify compounds as either toxic and non-toxic by 
finding a separation line that maximizes the minimal dis-
tance to any of the compounds while constraining the errors 
by a constant. Based on the 28 training compounds (Fig. 7d) 
the classification performance was assessed using leave-one-
out cross-validation.
The in vitro  EC10 (median, 48 h incubation) and Cmax 
(total, general circulation, 95% CI) were used as input 
parameters. This resulted in 28 out of 30 correct predictions 
(Fig. 7d), and thus a sensitivity, specificity and accuracy of 
100, 87.3, and 93.3%, respectively. The incorrect predic-
tions were for APAP, which at a therapeutic dose (14 mg/kg) 
was falsely predicted as hepatotoxic. The second false posi-
tive was glucose. A rich meal may increase blood glucose 
levels from approximately 90 to 219 mg/dl (5.0–12.2 mM), 
which despite a prediction of ‘hepatotoxic’, is not expected 
to have adverse effects on the liver. The accuracy was not 
improved when expression of the seven genes was addition-
ally included as an input parameter (Supplement 11), which 
agrees with the observation that TSI did not improve when 
gene expression was considered in addition to cytotoxicity.
An overall classifier was obtained by fitting an SVM 
classifier on all 30 compounds using the same input vari-
ables  (EC10 median, 48 h incubation and Cmax, total, general 
circulation, 95% percentile) as for the leave-one-out classi-
fiers. This classifier was applied to eight independent test 
substances known to be either hepatotoxic (leflunomide, 
nevirapine, tolcapone and troglitazone) or non-hepatotoxic 
(ethyl-, propyl-, butyl- and isobutylparaben) at specific blood 
concentrations (Fig. 7d). The classifier properties reflect the 
proportion of hepatotoxic compounds (here: 14 of total 30). 
Therefore, the present classifier was calibrated for test data 
Fig. 7  Gene expression, pharmacokinetic parameters and classifier 
construction. a Improvement of the TEI by combining cytotoxicity 
with gene expression. The TEI of cytotoxicity  (EC10) alone is indi-
cated by the red dot. Combination of cytotoxicity  (EC10, median) 
with three genes, CYP3A7, CYP1B1 and a third gene (G6PD, 
SULT1C2 or TUBB2B) leads to the highest TEI. b Extrapolation plot 
combining cytotoxicity  (EC10) and expression of CYP3A7, CYP1B1 
as well as G6PD, one of the optimal gene combinations of gene 
expression with cytotoxicity. The  EC10 of the three donors is indi-
cated by diamonds. Gene expression is indicated by triangles (lack 
of a triangle means that no alert for gene expression was obtained). 
The dashed line represents the iso-concentration line. c Analysis of 
TSI and TEI based on cytotoxicity  (EC10) for the following phar-
macokinetic parameters: Cmax, total (protein bound and free) con-
centration after a single dose (WB Cmax total); Cmax, total concentra-
tion, steady state after repeated doses (WB Cmax ss total); average 
concentration, total, after repeated doses (WB av ss total); Cmax, free 
(non-protein bound) concentration after a single dose (WB Cmax free); 
Cmax, free concentration, steady state, after repeated doses (WB 
Cmax ss free); average, free concentration, steady state, after repeated 
doses  (WBav ss free); portal vein Cmax, total concentration after a sin-
gle dose (PV Cmax total); portal vein steady state Cmax after repeated 
doses, total concentration (PV Cmax ss total); average concentration 
in the portal vein, steady state after repeated doses total concentra-
tion  (PVav ss total). All parameters are given for the mean, 5% as well 
as 95% percentile of a population, indicated by the circles, squares 
and triangles, respectively. The Cmax and Cmax ss is based on blood the 
cav,ss and portal vein is based on plasma. d Support vector machine 
(svm) classifier and performance metrics based on cytotoxicity 
 (EC10). Training compounds were assessed by leave-one-out cross-
validation, while the test compounds were assessed by the classifier 
built on the training compounds. The vertical dotted line indicates 0.5 
probability of toxicity; compounds with lower or higher probabilities 
of toxicity are classified as non-hepatotoxic or hepatotoxic, respec-
tively. Performance measures refer to the training compounds. Abbre-
viations of the training and test compounds are defined in Supplement 
1 (color figure online)
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with a similar number of hepatotoxic and non-hepatotoxic 
compounds. If this proportion will differ in future stud-
ies, adjustment of the predicted probabilities derived from 
the SVM will be required. Tested concentrations, toxicity 
information, pharmacokinetics, raw data and  EC10 values 
are given in Supplement 12. The eight independent test 
compounds were added to the optimized extrapolation plot 
(Fig. 8a). All non-hepatotoxic compounds were located in 
a region at least three orders of magnitude below the iso-
concentration line in the extrapolation plot. Blood concen-
trations of ethyl-, propyl-, butyl- and isobutylparaben are 
known from biomonitoring studies, and such exposure levels 
are not expected to cause an increased risk of hepatotoxicity 
(Azzouz et al. 2016; Frederiksen et al. 2011; Shekar et al. 
2016; Sandanger et al. 2011; Mulla et al. 2015; Nellis et al. 
2013). In contrast, the four hepatotoxic compounds were 
located in the hepatotoxic area delineated by the original set 
of compounds (Fig. 8a). Using the SVM classifier trained 
on the 28 original compounds, the independent eight com-
pounds were all correctly classified as either hepatotoxic or 
non-hepatotoxic (Fig. 7d).
The purpose of the analysis with eight independent com-
pounds was to check whether the separation line between 
hepatotoxic and non-hepatotoxic compounds established by 
the SVM classifier is plausible. A real validation of the pre-
dictive performance in terms of sensitivity, specificity, etc., 
would require the testing of more compounds with different 
mechanisms of action and varying degrees of hepatotoxic-
ity, not chosen to be only on the opposite extremes of the 
spectrum with regard to hepatotoxicity as for the present 
set of compounds. Nevertheless, the successful separation 
of the hepatotoxic and non-hepatotoxic compounds studied 
here allowed us to proceed with the next step in the work-
ing pipeline (Fig. 2), the extrapolation from in vitro alert 
concentrations to in vivo blood concentrations.
Estimation of the risk of hepatotoxicity at specific 
blood concentrations of test compounds
An important question is whether the probability of hepa-
totoxicity caused by specific in vivo blood concentrations 
can be extrapolated based on in vitro alert concentrations. 
The systematic degree of separation of hepatotoxic and non-
hepatotoxic compounds observed across the entire in vitro 
concentration range (Fig. 5c) suggests that such an extrapo-
lation may be possible. As described above, a SVM classifier 
was used to identify the line that best separates the hepa-
totoxic and the non-hepatotoxic compounds. A compound 
located exactly on this line has a 50% probability of belong-
ing to the hepatotoxic category (Fig. 8b). As a consequence, 
the intersection of the in vitro concentration  (EC10, median, 
48 h incubation) with this line can be used to estimate an 
in vivo concentration (Cmax) with a probability of 50% that it 
belongs to the hepatotoxic category (red symbols). It should 
be considered that the 50% probability of hepatotoxicity sce-
nario does not mean that 50% of the individuals will suffer 
from hepatotoxicity; belonging to the hepatotoxic category 
means a risk far below 50% for individual patients. The risk 
for each hepatotoxic compound has been defined in Sup-
plement 1 (‘hepatotoxicity information’). For example, oral 
doses of ketoconazole (one of the hepatotoxic compounds) 
caused hepatotoxicity in 0.007–0.05% and liver enzyme 
elevations in 4–20% of all treated patients.
Application of the extrapolation procedure to the four 
hepatotoxic test compounds (leflunomide, nevirapine, tol-
capone and troglitazone) led to calculated in vivo blood 
concentrations that are related with a 50% probability of 
hepatotoxicity of 0.050, 2.55, 1.46, and 0.61 µM, respec-
tively. Using a similar procedure, blood concentrations with 
a lower probability of hepatotoxicity, e.g., based on a 5% 
or 1% probability of hepatotoxicity, can also be calculated 
(Fig. 8b).
Estimation of an acceptable daily intake based 
on in vitro data
For all compounds studied so far, human hepatotoxicity 
and associated blood concentrations were known. How-
ever, often this knowledge is not available (ab initio toxicity 
evaluation). Pulegone was chosen as an example to estab-
lish an acceptable daily intake concerning hepatotoxicity. 
Pulegone is a naturally occurring organic compound used 
in flavoring agents and in the fragrance industry. High doses 
caused hepatotoxicity in rats (Khojasteh et al. 2012; Chen 
et al. 2011). Therefore, knowing which concentrations in 
blood increase the risk of human hepatotoxicity is of inter-
est. Cytotoxicity testing in PHH from three donors resulted 
in a median  EC10 of 1.27 mM (Fig. 8b, c). Application of 
the above-mentioned extrapolation procedure identified 
30.3 µM as the blood concentration (Cmax) corresponding 
to a 50% probability of belonging to the hepatotoxic cat-
egory, and 1.57 µM as the concentration corresponding to a 
5% probability (Fig. 8c, d). The latter concentration associ-
ated with a 5% probability of hepatotoxicity may serve as a 
basis for derivation of an acceptable daily intake dose (ADI). 
Reverse PBPK modeling for repeated oral doses indicated 
that a blood concentration (Cmax) of 1.57 µM corresponds 
to 268 µg pulegone/kg body weight/day (Fig. 8c), which 
may be considered an in vitro derived ADI. This extrapola-
tion can also be performed for stricter probability levels, for 
example, a 1% probability will result in an in vitro derived 
ADI of 51 µg/kg/day (Fig. 8d). ADIs based on 28 days oral 
toxicity studies in rats by the established method ranged 
between 100 and 750 µg/kg/day (HMPC 2016; CEFS/SCF/
CS 2002). Tested concentrations, raw data and  EC10 values, 
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A Lowest positively tested
concentration in vitro
(alert concentration):
1.27 mM
Blood concentrations associated
with a certain probability for the
hepatotoxic category:
0.5 probability: 30.3 µM 
0.05 probability: 1.57 µM
Repeated oral doses that
cause a Cmax of 1.57: 
268 µg/kg/day
(in vitro ADI)
Probability 
of 
hepatoxicity
Linear 
equaon
Cmax
[µM]
Single 
oral dose 
[mg]
Repeated 
oral dose 
[mg]
Repeated 
oral dose 
[mg/kg]
0.5 y = -1.600 + 0.796x 30.34 4000 350 4.944
0.1 y = -2.559 + 0.796x 3.33 86 40 0.565
0.05 y = -2.885 + 0.796x 1.57 41 19 0.268
0.01 y = -3.606 + 0.796x 0.299 7.5 3.6 0.051
0.005 y = -3.910 + 0.796x 0.148 3.8 1.8 0.025
0.001 y = -4.615 + 0.796x 0.029 0.72 0.35 0.005
Established ADI:
HMPC (2016): 375-750                 
µg/kg/day
CEFS (2002): 100 µg/kg/day
28 days oral toxicity study in rats: 
NOAEL: 20 mg/kg/day; hepato-
toxicity; safety factor: 200 
Average intake of a European 
population: 0.04 µg/kg/day
B
D
C
Fig. 8  Predictions and comparison with published data. a Analy-
sis of eight further hepatotoxic and non-hepatotoxic compounds not 
included in the first set of test substances in PHH. The red and green 
symbols correspond to the training compounds, similar to Fig. 5c but 
without the illustration of error ranges. The additional non-hepato-
toxic substances (ethylparaben, butylparaben, isobutylparaben, pro-
pylparaben) are represented by black triangles, the additional hepa-
totoxic compounds (leflunomide, nevirapine, tolcapone, troglitazone) 
by black dots. b Ab  initio risk evaluation of pulegone. The red and 
green symbols show the training compounds similar to a. The black 
diagonal line (0.5) indicates optimal separation of hepatotoxic (red) 
and non-hepatotoxic (green) compounds. If a substance lies on this 
line its probability to either belong to the hepatotoxic or non-hepa-
totoxic compounds is 0.5. Correspondingly, the 0.1, 0.05, 0.01 and 
0.005 probabilities are indicated by dashed diagonal lines. Data of 
pulegone are given in blue color. 1.27 mM is the  EC10 (median; 48 h 
incubation) of the cytotoxicity of pulegone. The dashed blue lines 
indicate that pulegone intersects the 0.01 and 0.05 probability lines at 
blood concentrations (Cmax) of 0.299 and 1.57 µM, respectively. The 
blue line represents the iso-concentration line (Iso-line). c Derivation 
of an acceptable daily intake (ADI) for the 0.05 probability line and 
comparison to established ADIs derived from hepatotoxicity in rats. 
d Linear equations, and Cmax in blood for pulegone for the individual 
probability lines. Moreover, single and repeated oral doses are given 
that would result in the corresponding Cmax in blood (color figure 
online)
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as well as reverse modelling of the pulegone case study are 
given in Supplement 12.
Comparison with publicly available data 
and analysis by margin of safety
Recently, the cytotoxicity of 110 compounds (69 hepatotoxic 
and 41 non-hepatotoxic) was tested in spheroid cultures of 
human hepatocytes (Proctor et al. 2017). Besides informa-
tion on hepatotoxicity, the  EC50 of cytotoxicity and the Cmax 
of the test compounds were also published (Supplementary 
material 2 in Proctor et al. 2017). For comparison, we pre-
pared an extrapolation plot using the data provided by Proc-
tor et al. (2017) in their supplementary information (Fig. 9a), 
resulting in a TSI of 0.773 and a TEI of 0.788. Although the 
compounds were not perfectly separated, the trend is that 
the non-hepatotoxic compounds are further below the iso-
concentration line compared to the hepatotoxic compounds.
Previous studies have mainly used the margin of safety 
(MoS) method to evaluate hepatotoxicity in vitro. To allow 
a comparison, our data was also analyzed by MoS, where 
the ratio of the  EC50 or  EC10 to the Cmax in blood were plot-
ted on the y-axis; whereas, hepatotoxic compounds (DILI 
concern) and controls (no DILI concern) are shown on the 
x-axis (Fig. 9b–d). This method was applied to plot the pub-
lished data of Proctor et al. (2017), together with the data 
used in the present study. Proctor et al. subdivided “DILI 
concern” compounds into “severe”, “high”, and “low” 
(Fig. 9b). While the most severe DILI concern compounds 
showed a MoS lower than 20, a relatively high fraction of 
the high and low DILI concern compounds were above 20. 
Data from the present study (Fig. 9c, d) showed that using 
the median  EC10 of three donors allows for a better differen-
tiation between hepatotoxic and non-hepatotoxic compounds 
than the  EC10 minimum or maximum (Fig. 9c). Moreover, 
 EC10 values (Fig. 9c) differentiated better than  EC50 values 
(Fig. 9d); the  EC50 resulted in more hepatotoxic compounds 
with a MoS > 20 compared to the corresponding  EC10 data.
HepG2 instead of PHH for in vitro testing
The human hepatocyte-based test method established in 
this study successfully distinguished hepatotoxic and non-
hepatotoxic compounds. However, PHH are expensive, 
compared to HepG2 cells. It is unknown whether using the 
same approach with HepG2 cells would generate compa-
rable results to those obtained with PHH. Therefore, the 
same experiments as described for PHH were performed 
using HepG2 cells, including cytotoxicity and expression 
of the seven genes. Extrapolation plots using the median 
 EC10 (Fig. 10a) and the combination of median  EC10 with 
CYP3A7, CYP1B1 and G6PD (Fig. 10b) showed that lower 
metrics for test performance were obtained for HepG2 than 
for PHH. The TSI for PHH was 0.996 compared to 0.911 
for HepG2. The TEI was also lower for HepG2 (0.844 and 
0.810 for PHH and HepG2, respectively). The difference 
between HepG2 cells and PHH is illustrated in Fig. 10c 
where ratios of the median  EC10 values of HepG2 and PHH 
are plotted for each compound (corresponding analysis for 
 EC50: Supplement 6). The highest ratios were obtained for 
NAC, CBZ, BPR and ETOH, where PHH were at least ten-
fold more susceptible than HepG2 (Fig. 10c). In contrast, 
HepG2 cells were more susceptible to other compounds, 
including TSN and VPA. The results show that 6 out of 28 
tested compounds resulted in more than tenfold differences 
between PHH and HepG2.
Despite the inferior performance metrics of the HepG2-
based in vitro test method, HepG2 cells may still be used 
for exploratory studies. In an attempt to improve the per-
formance of the HepG2-based test, a glutathione (GSH) 
assay was performed with all test compounds. A combined 
analysis of cytotoxicity (median  EC10) and GSH deple-
tion (median  EC10), where combination means the use of 
the more sensitive of the two readouts for each compound, 
improved TSI and TEI compared to either GSH depletion 
or cytotoxicity alone (Fig. 10d). In addition, addition of 
measuring GSH content to the combined cytotoxicity- and 
gene expression-based test battery (CYP3A7, CYP1B1 and 
G6PD) improved TSI and TEI (all analyses based on median 
values) (Fig. 10d). Therefore, it should be evaluated in the 
future, whether the GSH assay also improves hepatotoxicity 
analysis in PHH.
Discussion
We present a method for the prediction of hepatotoxicity of 
test compounds and for estimation of the probability of hepa-
totoxicity at specific blood concentrations based on in vitro 
test results with cryopreserved or freshly isolated human 
hepatocytes. The test performance was optimized for a train-
ing set of compounds based on the here established metrics, 
TSI and TEI. An optimized set of parameters was then used 
for the analysis of independent compounds to estimate blood 
concentrations associated with an increased probability of 
hepatotoxicity. Based on reverse modeling, corresponding 
oral doses and an acceptable daily intake can thereafter be 
derived. Advantages of the method established here are that 
(1) metrics-based test system optimization allows systematic 
integration of further test parameters and iterative cycles of 
optimization and validation to improve the test performance; 
(2) based on in vitro data it is possible to derive oral doses 
that either cause an increased risk of toxicity or that can be 
considered as acceptable.
One application of the test method is to evaluate test com-
pounds for which intended blood concentrations are already 
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known. Even early in drug development when pharmacoki-
netic studies are not yet available, an approximation of the 
required blood concentration is often available, e.g., the 
bactericidal concentration in vitro when novel antibiotics 
are developed. The test method introduced here could then 
estimate whether this concentration leads to an increased 
risk of hepatotoxicity or can be considered acceptable. 
Moreover, biomonitoring studies in environmental toxicol-
ogy identify concentrations of xenobiotics in blood; the test 
method established here will inform about the associated 
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Fig. 9  a Extrapolation plot of recently published cytotoxicity data 
generated with spheroids of primary human hepatocytes (data from 
Proctor et  al. 2017). Red and green symbols indicate compounds 
with and without DILI concern, respectively. In the data set of Proc-
tor et al., exact  EC50 values (e.g., 100 µM) were given for some com-
pounds, indicated by circles in this figure; for other compounds  EC50 
values could not be reached (data given e.g., as > 100 µM) indicated 
by triangles in the present extrapolation plot. b Presentation of the 
data of Proctor et al. (2017) by the ‘margin of safety’ (MoS) method. 
The y-axis presents the ratio of in vitro cytotoxicity  (EC50) in PHH 
and the Cmax in blood. Compounds with DILI concern were grouped 
into severe, high and low (red symbols). For controls (no DILI con-
cern), compounds with and without elevated liver enzymes (EE) were 
differentiated (green symbols). The numbers on top of the panel, e.g., 
(17/23), represent the number of compounds below a MoS of 20 and 
the total number of compounds. c Data of the present study presented 
by the MoS method, using the  EC10 as a measure of cytotoxicity. 
Data for the maximum, median and minimum  EC10 (min, med, max) 
of three donors are shown. d Corresponding data to d for  EC50 values 
to allow a direct comparison to the data of Proctor et  al. (2017) in 
d who also used  EC50 values. 1EE indicates a transient elevation of 
liver enzymes without histological tissue damage (Proctor et al. 2017) 
(color figure online)
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risk of hepatotoxicity. A second application comprises 
novel compounds for which only little information is avail-
able, where the method allows estimation of acceptable oral 
doses. A limitation of this approach is that reverse modeling 
for novel compounds is only possible with some degree of 
uncertainty.
An almost optimal differentiation between the analyzed 
hepatotoxic (n = 18) and non-hepatotoxic (n = 20) com-
pounds (including training and test sets) was achieved based 
on the  EC10 of the cytotoxicity test after a 48 h incubation 
period both using the extrapolation plots and the classi-
fier. Therefore, it is not surprising that a 7-gene signature, 
which on its own also differentiated the hepatotoxic from 
Fig. 10  Hepatotoxicity prediction based on HepG2 cells and com-
parison to PHH. a Extrapolation plot of HepG2 cells using cytotoxic-
ity  (EC10, median, 48 h incubation) as in vitro parameter (x-axis) and 
the Cmax (total concentration, 95% CI) on the y-axis. b Extrapolation 
plot with combined analysis of cytotoxicity  (EC10, median) and gene 
expression (CYP3A7, CYP1B1, G6PD). c Ratio plot comparing cyto-
toxicity in HepG2 and PHH. Ratios were calculated by dividing  EC10 
(median) values measured with HepG2 cells by those obtained with 
of PHH. d Influence of the additional consideration of glutathione 
(GSH) depletion on TSI and TEI. Cytotoxicity  (EC10, median), as 
well as a combination of cytotoxicity and the expression of CYP3A7, 
CYP2B1 and G6PD were compared with and without the additional 
consideration of GSH depletion using the median  EC10. The dashed 
line in a and b represents the iso-concentration line
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non-hepatotoxic compounds, did not further improve the 
already close to optimal TSI, and only slightly increased the 
TEI, when combined with cytotoxicity. It is plausible that 
cytotoxicity plays a major role for the prediction of hepato-
toxic blood concentrations. However, the present data should 
not be interpreted to mean that gene expression cannot add 
independent information when predicting hepatotoxic blood 
concentrations. Therefore, to show that gene expression can 
contribute to the predictive performance, it will be impor-
tant to identify compounds where hepatotoxic blood con-
centrations are strongly overestimated based on cytotoxicity 
alone. Such compounds, which induce liver toxicity based 
on mechanisms other than cytotoxicity, will then have to be 
investigated using methods that identify alternative mecha-
nisms, for example attraction of immune cells by cytokine 
release or compromised bile salt transport.
A SVM classifier with cytotoxicity  (EC10, median, 48 h 
incubation) and Cmax (total concentration, general circula-
tion, 95% percentile) as input variables correctly predicted 
whether a compound is hepatotoxic or not for 28 out of 
30 compound-exposure scenarios in a leave-one-out cross 
validation procedure, and correctly predicted further eight 
independent test compounds as either hepatotoxic or non-
hepatotoxic. A false positive result was obtained for a non-
hepatotoxic blood concentration of the analgesic acetami-
nophen (APAP). APAP is not hepatotoxic at therapeutic 
doses of 14 mg/kg (corresponding to a Cmax of 0.109 mM), 
but causes a high risk of hepatotoxicity at accidental or 
suicidal doses of 140 mg/kg or higher (https ://liver tox.nih.
gov/Aceta minop hen.htm). This corresponds to a modeled 
Cmax of 1.21 mM. Cytotoxicity analysis of APAP identified 
2.2 mM as the  EC10 and an alert for G6PD at 5 mM. How-
ever, the small range between non-toxic and cytotoxic doses 
leads to a situation where the non-cytotoxic APAP blood 
concentration still clusters into the hepatotoxic range of the 
extrapolation plot, which results in a false positive classifica-
tion. The second false positive compound was glucose. After 
the consumption of a rich standard meal, blood glucose may 
increase from approximately 90–219 mg/dl (95% CI) (Freck-
mann et al. 2007), which we considered a non-hepatotoxic 
exposure when designing the study.
Establishment of the method described in the present 
study depends on existing knowledge of the blood–con-
centration–time profile resulting from a specific exposure 
scenario. Available information is most comprehensive for 
pharmaceutical drugs, for which both precise pharmacoki-
netics and hepatotoxicity data for large numbers of patients 
are available. Therefore, most of the compounds analyzed 
in the current work were pharmaceutical drugs. However, 
to study a wide range of diverse substances other chemicals 
were also included. Use of body lotions with the preservative 
methylparaben (MePa) may lead to blood concentrations of 
0.009 µM MePa (Guo et al. 2014), which is not hepatotoxic 
in vivo and also orders of magnitude below hepatotoxic con-
centrations according to the in vitro method with cultivated 
hepatocytes. Dimethyl sulfoxide (DMSO) has been used in 
gels (Roth and Shainhouse 2004) which may lead to blood 
concentrations of 108 µM that are clearly below cytotoxic 
levels. Alcohol abuse with a daily oral consumption of more 
than 16 g ethanol leads to steatosis in approximately 90% 
of individuals (Crabb 1999; Massey and Arteel 2012). For 
this exposure scenario, a blood peak concentration (total 
concentration, whole blood, 95% percentile) of 10.1 mM 
was modeled. In contrast, transdermal exposure caused 
by disinfection aerosol spray leads to an exposure of up to 
9.72 g ethanol (Pendlington et al. 2001), for which a blood 
peak concentration (whole blood, total, 95% percentile) 
of 5.76 µM was modeled, which is considered non-toxic 
(Kramer et al. 2007). The extrapolation plot and the SVM 
classifier could separate hepatotoxic and non-hepatotoxic 
ethanol blood concentrations.
The novel metrics, TSI and TEI enable quantitative 
assessment of in vitro test performance and enable a com-
parison of how performance is influenced by individual 
parameters. A basic question addressed with this approach 
was which cutoff should be used to define a cytotoxic effect. 
In toxicology, the  EC50 defined as the concentration that 
reduces viability by 50% is often applied. However, sys-
tematically increasing the EC cutoff revealed a strong 
decrease in the TEI in the range from  EC10 to  EC80, with 
a concomitant decrease in the TSI. Therefore, it appears to 
be important to identify concentrations where cytotoxicity 
first becomes evident. Another practical question addressed 
was whether the median, maximum or minimum  EC10 value 
perform better when hepatocytes from several donors are 
analyzed. Should, for example, the minimum  EC10 yield 
higher TSI and TEI values, then the test performance would 
be improved by identifying particularly susceptible hepato-
cyte batches. Moreover, cryopreserved hepatocyte batches 
are available where cells of several donors have been pooled 
(Hengstler et al. 2000; Hewitt et al. 2007). However, this 
pooled approach was avoided in the present study to deter-
mine whether it was relevant to use particularly susceptible 
hepatocytes. The present results show that the median values 
of cytotoxicity from three donors led to a higher TSI than the 
corresponding minima or maxima values. Conversely, the 
minima (e.g.,  EC10 of the most susceptible donor) yielded a 
higher TEI. Since, however, a higher TSI is preferred over 
a higher TEI, the median  EC10 currently represents the best 
available parameter to describe cytotoxicity in the data set 
analyzed here. The median value works best for the over-
all strategy, since it does not seem necessary to identify 
particularly susceptible donors to gain an optimal TSI. On 
the other hand, pooled hepatocyte batches (Hengstler et al. 
2000) should still be considered with caution, because the 
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data obtained will represent a mean which—in contrast to 
the median—is outlier-sensitive.
Another question addressed in this study was how long 
cultivated hepatocytes should be exposed to test compounds, 
and whether repeated exposures are superior to a single addi-
tion of test compound (Gu et al. 2018; Godoy et al. 2013). 
Our results demonstrated that a two-day exposure period 
of the test compound (with only one addition of test com-
pound at the morning after thawing and plating) lead to a 
higher TSI and TEI compared to 24 h or 7-day exposure 
with repeated culture medium changes containing fresh test 
compound. The better results obtained after 2 days com-
pared to a single day of exposure is plausible since some 
test compounds require more than 24 h to develop their full 
toxic potential (Gu et al. 2018). However, it was surprising 
that the longer incubation protocol (7 days) and repeated 
exposures did not further improve the test performance. An 
explanation may be that hepatocytes exhibit gene expression 
alterations that increase with the length of the cultivation 
period, leading to a decrease in the hepatocyte differentiation 
status (Godoy et al. 2015; Zellmer et al. 2010; Rowe et al. 
2013). Moreover, hepatotoxic effects caused by repeated 
doses in vivo often require the involvement of cell types 
other than hepatocytes, such as stellate cells (Hammad et al. 
2014, 2017), endothelial cells (Hoehme et al. 2010; Ghallab 
et al. 2016, 2018), and cholangiocytes (Jansen et al. 2017; 
Vartak et al. 2016; Ghallab et al. 2018), which are not repre-
sented adequately in currently available in vitro methods. If, 
however, hepatocytes are the primary target of a hepatotoxic 
compound, it seems that this type of toxicity can be ade-
quately identified by a single compound exposure for 48 h, at 
least for the compound set tested in the present study. Since 
this approach is easier and enables a higher throughput than 
long-term cultures with hepatocytes in more complex sys-
tems (e.g. Frey et al. 2014; Godoy et al. 2013), it was used 
in the present study. Furthermore, it was tested whether an 
inexpensive and easy-to-handle permanent human hepato-
cyte cell line may be used for the in vitro test method instead 
of the more challenging PHH. Regarding TSI and TEI, the 
HepG2 cell line used in the present study performed worse 
compared to PHH and is, therefore, not considered a PHH 
replacement.
In previous studies, the blood or plasma peak concentra-
tion (Cmax) has routinely been used to extrapolate between 
in vitro data and the in vivo situation concerning DILI (e.g. 
Proctor et al. 2017), as well as toxicity of other organs, e.g., 
nephrotoxicity (Sjogren et al. 2018; Sjogren and Hornberg 
2018). However, a comprehensive analysis to determine 
which pharmacokinetic parameter is optimal for this pur-
pose has not yet been performed. The present study dem-
onstrated that total (i.e., protein bound and free) concentra-
tions improve in vitro–in vivo extrapolation compared to free 
(non-protein bound) concentrations, based on the TSI/TEI 
concept. It should be considered that the cell culture medium 
for hepatocytes used in the present study is serum-free with-
out albumin (Schug et al. 2013; Godoy et al. 2013); whereas, 
human blood contains 35–53 g albumin/l. A further result 
from the analysis of pharmacokinetic parameters was that 
the 95th percentile of Cmax of a population led to a higher 
TEI than the mean or the 5th percentile. An explanation may 
be that patients with the highest drug concentrations in blood 
are at the highest risk of hepatotoxicity, and a better agree-
ment between in vitro and in vivo data may be obtained if 
the extrapolation is based on 95th percentile concentrations. 
It is also plausible that Cmax in the portal vein resulted in a 
higher TEI than the compound concentration in the general 
circulation. After oral administration, concentrations in the 
portal vein are usually higher due to the first pass effect of 
the liver (Mielke et al. 2011). However, a higher TEI for 
portal vein Cmax was obtained at the expense of a worse TSI. 
An explanation may be that liver tissue is exposed longer to 
the blood from the general circulation than to the higher but 
transient concentrations in the portal vein during compound 
absorption from the intestine. Altogether, the 95th percentile 
of the total, maximal blood concentration in the general cir-
culation allowed for the best separation (TSI) of hepatotoxic 
and non-hepatotoxic compounds of all analyzed pharma-
cokinetic parameters for the here studied set of compounds.
Once established, it was necessary to determine whether 
the method resulted in correct predictions of independent 
compounds. We tested additional hepatotoxic and non-hepa-
totoxic compounds (n = 8) that all clustered to the expected 
regions of the extrapolation plot and were correctly pre-
dicted by the classifier. In the future, a greater number of 
compounds will have to be tested; it will also be necessary 
to study whether in vitro prediction by the method estab-
lished here depends on the mechanisms of action of test 
compounds. Nevertheless, the favorable results encouraged 
us to use the blood concentrations estimated to correspond 
to a 50% or 5% probability of hepatotoxicity for the com-
pound to perform a case study for de novo risk evaluation of 
pulegone, an organic compound present in teas, spices and 
perfumes (Zárybnický et al. 2018; Gordon and Khojasteh 
2015). Since pulegone has been reported as hepatotoxic 
in rats (Khojasteh et al. 2012; Chen et al. 2011), there is 
some interest in human risk evaluation of hepatotoxicity. 
Pulegone is a relatively non-toxic compound with a Cmax of 
1.27 mM  (EC10, median, 48 h incubation). Using the tech-
nique established here, this  EC10 value corresponds to a Cmax 
of 1.57 µM that is associated with a 5% probability to belong 
to the hepatotoxic category, which after reverse modeling for 
repeated oral doses corresponds to 268 μg/kg/day. Accept-
able daily intake (ADI) derived by the established method 
based on toxicity studies in rats ranged between 100 and 
750 µg/kg/day (CEFS/SCF/CS 2002; HMPC 2016). There-
fore, the ADI derived by the novel in vitro method would be 
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in the range of ADIs established in animal studies. However, 
a limitation is that it has not yet been systematically studied 
which probability (of compound to belong to the hepatotoxic 
category) is most appropriate for the establishment of an 
ADI in vitro. The use of an estimated blood concentration 
corresponding to a 1% probability would, for example, result 
in an ADI of 51 µg/kg/day. Therefore, a next important step 
will be to compare a larger number of in vitro and conven-
tionally established ADIs and identify the most appropriate 
probability for extrapolation.
Four prior studies used PHH to predict human hepato-
toxicity (Proctor et al. 2017; Xu et al. 2008; Khetani et al. 
2013; Vorrink et al. 2018). Proctor et al. (2017) provided 
in vivo Cmax and  EC50 values of the cytotoxicity tests for 
individual compounds. This allowed us to calculate a TSI 
of 0.773 and a TEI of 0.788, which are lower compared 
to the corresponding values (TSI 0.996, TEI 0.887) of the 
present study. This difference is not necessarily explained 
only by the different types of in vitro methods, but may also 
be due to the tested concentration ranges. One difference 
to our study is that we escalated the concentrations of test 
compounds until either cytotoxicity was obtained or the lim-
its of solubility were reached. Using this strategy, an  EC10 
could be derived for 27 of the 28 tested compounds, and 
the only negative compound still showed a positive result 
when gene expression was used. Therefore, it was possible 
to identify positive in vitro test concentrations for all com-
pounds, including the negative controls. In contrast, 24 of 
69 hepatotoxic compounds and 31 of 41 non-hepatotoxic 
compounds studied by Proctor et al. (2017) were not tested 
up to cytotoxic levels (and were reported as  EC50 > ”highest 
tested concentration”); therefore, the difference in results 
between both studies may also be due to the choice of test 
compound concentrations.
A further limitation of previous studies is that hepatocytes 
of only one human donor were tested per compound (Proctor 
et al. 2017; Vorrink et al. 2018); whereas, the present study 
analyzed three human donors. This difference is likely to 
have an impact on the accuracy of the data. In contrast to 
the study by Proctor et al., no raw data,  EC50 or  EC10 data of 
the individual compounds were provided by Vorrink et al. 
(2018), which made it impossible to directly compare their 
finding to ours. Such comparisons would have been of inter-
est, because there were some atypical dose response rela-
tionships, where toxicity was observed at lower concentra-
tions, but decreased or disappeared at higher concentrations 
(Vorrink et al. 2018). For instance, iproniazid was reported 
to be cytotoxic at 1 × Cmax but not at 20 × Cmax; similarly, 
propranolol was reported to be cytotoxic at 5 × Cmax but not 
at 20 × Cmax. This is different to our study where we did not 
observe a loss in cytotoxicity at higher concentrations for 
any of the tested compounds. Moreover, the authors reported 
a specificity of 100% (Vorrink et al. 2018), which from the 
data presented is difficult to interpret. One of the DILI nega-
tive compounds (propranolol) was reported as positive at 
5 × Cmax, but the test result was nevertheless interpreted as 
negative. Another potential concern is that the highest con-
centration (20 × Cmax) was not tested for some DILI nega-
tive compounds, for example, aminoglutethimide, practolol 
and ternozolomide, possibly because of solubility problems. 
However, this was not explicitly stated. These “DILI nega-
tive” compounds were predicted to be negative based only 
on the two lowest tested concentrations (Cmax and 5 × Cmax); 
however, some “severe DILI” compounds also tested nega-
tive at the two lowest concentrations, only exhibiting cyto-
toxicity at the highest (20 × Cmax) concentration, for exam-
ple alpidem, clomipramine, dihydralazine, disulfiram, etc. 
Therefore, it is difficult to differentiate these compounds 
from the aforementioned negatively predicted compounds, 
where data at 20 × Cmax are not available. Another critical 
aspect is that APAP was considered a true positive. How-
ever, this analysis was based on a Cmax for APAP of 136 µM, 
which corresponds to a therapeutic dose of approximately 
14 mg/kg—a safe dose which does not cause DILI (https ://
liver tox.nih.gov/Aceta minop hen.htm).
In conclusion, the workflow established in the present 
study allows for systematic test optimization by quantita-
tively evaluating the influence of individual test parameters 
on the performance of the in vitro method by the novel 
performance metrics TSI and TEI. It allows classification 
of compounds as hepatotoxic or non-hepatotoxic and pro-
vides an extrapolation procedure to estimate the probability 
of hepatotoxicity for specific blood concentrations and the 
associated oral doses of test compounds for ab initio evalu-
ation of chemicals.
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